Flow cytometry data
. | Bone marrow . | . | Spleen . | . | Lymph node . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Surface marker . | SCLtTA/BCR-ABL (n = 13) . | Controls (n = 11) . | SCLtTA/BCR-ABL (n = 13) . | Controls (n = 11) . | SCLtTA/BCR-ABL, % (n = 8) . | Controls, % (n = 3) . | |||
| Gr-1 | 62 ± 18† | 47 ± 11 | 21 ± 13† | 8 ± 2 | 0-45 | 11-14 | |||
| Gr-1loMac-1 +* | 23 ± 4† | 12 ± 2 | ND | ND | ND | ND | |||
| Gr-1 + Mac-1 +* | 52 ± 15† | 37 ± 8 | 17 ± 11† | 4 ± 2 | 0-25 | 2-7 | |||
| Mac-1 | 57 ± 16† | 42 ± 9 | 23 ± 11† | 13 ± 8 | 6-35 | 7-26 | |||
| Mac-1/B220 | 21 ± 10† | 8 ± 3 | 12 ± 6 | 9 ± 7 | 5-17 | 5-20 | |||
| Mac-1/Sca-1 | 12 ± 5† | 4 ± 2 | 10 ± 3 | 7 ± 5 | 1-15 | 6-43 | |||
| Mac-1/CD34 | 16 ± 6† | 6 ± 2 | 5 ± 3 | 2 ± 3 | 0-4 | 4-10 | |||
| B220 | 35 ± 13 | 30 ± 4 | 58 ± 13 | 54 ± 5 | 44-81 | 26-43 | |||
| Sca-1 | 20 ± 5† | 12 ± 5 | 48 ± 9† | 66 ± 10 | 10-72 | 50-83 | |||
| c-kit | 26 ± 9 | 22 ± 8 | 13 ± 8† | 4 ± 1 | 0-37 | 0-2 | |||
| BP-1/B220 | 15-43‡ | 8 ± 4 | 3-43‡ | 8 ± 4 | 0-91 | 1-4 | |||
| CD43/B220 | 10-37‡ | 8 ± 3 | 7-52‡ | 8 ± 3 | 15-77 | 6-25 | |||
| IgM/B220 | 13 ± 6 | 8 ± 2 | 17 ± 7† | 37 ± 4 | 7-31 | 9-26 | |||
| CD41 | 21 ± 10† | 11 ± 2 | 23 ± 7† | 14 ± 5 | 2-23 | 5-24 | |||
| Ter119 | 14 ± 7† | 22 ± 10 | 13 ± 9† | 5 ± 2 | 0-11 | 6-16 | |||
. | Bone marrow . | . | Spleen . | . | Lymph node . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Surface marker . | SCLtTA/BCR-ABL (n = 13) . | Controls (n = 11) . | SCLtTA/BCR-ABL (n = 13) . | Controls (n = 11) . | SCLtTA/BCR-ABL, % (n = 8) . | Controls, % (n = 3) . | |||
| Gr-1 | 62 ± 18† | 47 ± 11 | 21 ± 13† | 8 ± 2 | 0-45 | 11-14 | |||
| Gr-1loMac-1 +* | 23 ± 4† | 12 ± 2 | ND | ND | ND | ND | |||
| Gr-1 + Mac-1 +* | 52 ± 15† | 37 ± 8 | 17 ± 11† | 4 ± 2 | 0-25 | 2-7 | |||
| Mac-1 | 57 ± 16† | 42 ± 9 | 23 ± 11† | 13 ± 8 | 6-35 | 7-26 | |||
| Mac-1/B220 | 21 ± 10† | 8 ± 3 | 12 ± 6 | 9 ± 7 | 5-17 | 5-20 | |||
| Mac-1/Sca-1 | 12 ± 5† | 4 ± 2 | 10 ± 3 | 7 ± 5 | 1-15 | 6-43 | |||
| Mac-1/CD34 | 16 ± 6† | 6 ± 2 | 5 ± 3 | 2 ± 3 | 0-4 | 4-10 | |||
| B220 | 35 ± 13 | 30 ± 4 | 58 ± 13 | 54 ± 5 | 44-81 | 26-43 | |||
| Sca-1 | 20 ± 5† | 12 ± 5 | 48 ± 9† | 66 ± 10 | 10-72 | 50-83 | |||
| c-kit | 26 ± 9 | 22 ± 8 | 13 ± 8† | 4 ± 1 | 0-37 | 0-2 | |||
| BP-1/B220 | 15-43‡ | 8 ± 4 | 3-43‡ | 8 ± 4 | 0-91 | 1-4 | |||
| CD43/B220 | 10-37‡ | 8 ± 3 | 7-52‡ | 8 ± 3 | 15-77 | 6-25 | |||
| IgM/B220 | 13 ± 6 | 8 ± 2 | 17 ± 7† | 37 ± 4 | 7-31 | 9-26 | |||
| CD41 | 21 ± 10† | 11 ± 2 | 23 ± 7† | 14 ± 5 | 2-23 | 5-24 | |||
| Ter119 | 14 ± 7† | 22 ± 10 | 13 ± 9† | 5 ± 2 | 0-11 | 6-16 | |||
Bone marrow and spleen values are mean ± SD. ND indicates not determined.
Gr-1loMac-1 + cells were calculated as the fraction of the cells in gate R1 among the combined fractions of cells in R1 and R2, as shown in Figure 5B. Gr-1 + Mac-1 + cells represent the total number of Gr-1-and Mac-1-costaining cells.
P < .05 compared with controls (unpaired t test). Controls represent BCR-ABL (n = 8) or SCLtTA (n = 1) single-transgenic or wild-type (n = 2) mice.
Percentage range in mice with lymphoid phenotype.